{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:01:57Z","timestamp":1793394117682,"version":"4.5.0"},"reference-count":295,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102938"],"award-info":[{"award-number":["82102938"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202429"],"award-info":[{"award-number":["82202429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LBY23H080005"],"award-info":[{"award-number":["LBY23H080005"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LBY23H080004"],"award-info":[{"award-number":["LBY23H080004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LBY23H080001"],"award-info":[{"award-number":["LBY23H080001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Reactive oxygen species (ROS) serve as typical metabolic byproducts of aerobic life and play a pivotal role in redox reactions and signal transduction pathways. Contingent upon their concentration, ROS production not only initiates or stimulates tumorigenesis but also causes oxidative stress (OS) and triggers cellular apoptosis. Mounting literature supports the view that ROS are closely interwoven with the pathogenesis of a cluster of diseases, particularly those involving cell proliferation and differentiation, such as myelodysplastic syndromes (MDS) and chronic\/acute myeloid leukemia (CML\/AML). OS caused by excessive ROS at physiological levels is likely to affect the functions of hematopoietic stem cells, such as cell growth and self-renewal, which may contribute to defective hematopoiesis. We review herein the eminent role of ROS in the hematological niche and their profound influence on the progress of MDS. We also highlight that targeting ROS is a practical and reliable tactic for MDS therapy.<\/jats:p><jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1186\/s11658-024-00570-0","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T16:01:21Z","timestamp":1713110481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Role of reactive oxygen species in myelodysplastic syndromes"],"prefix":"10.1186","volume":"29","author":[{"given":"Qiangan","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-8531","authenticated-orcid":false,"given":"Jing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,14]]},"reference":[{"issue":"1","key":"570_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"570_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"570_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.molcel.2020.05.014","volume":"78","author":"A Strasser","year":"2020","unstructured":"Strasser A, Vaux DL. Cell death in the origin and treatment of cancer. Mol Cell. 2020;78(6):1045\u201354.","journal-title":"Mol Cell"},{"key":"570_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100646","volume":"47","author":"AB Sarmento-Ribeiro","year":"2019","unstructured":"Sarmento-Ribeiro AB, Scorilas A, Gon\u00e7alves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: clinical evidence. Drug Resist Updat. 2019;47: 100646.","journal-title":"Drug Resist Updat"},{"key":"570_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101870","volume":"42","author":"AC Boese","year":"2021","unstructured":"Boese AC, Kang S. Mitochondrial metabolism-mediated redox regulation in cancer progression. Redox Biol. 2021;42: 101870.","journal-title":"Redox Biol"},{"key":"570_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101674","volume":"37","author":"D Nolfi-Donegan","year":"2020","unstructured":"Nolfi-Donegan D, Braganza A, Shiva S. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. 2020;37: 101674.","journal-title":"Redox Biol"},{"issue":"7","key":"570_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41580-019-0123-5","volume":"20","author":"J Zhu","year":"2019","unstructured":"Zhu J, Thompson CB. Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019;20(7):436\u201350.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"570_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","volume":"22","author":"EC Cheung","year":"2022","unstructured":"Cheung EC, Vousden KH. The role of ROS in tumour development and progression. Nat Rev Cancer. 2022;22(5):280\u201397.","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"570_CR9","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1016\/j.molcel.2021.08.018","volume":"81","author":"C Lennicke","year":"2021","unstructured":"Lennicke C, Cochem\u00e9 HM. Redox metabolism: ROS as specific molecular regulators of cell signaling and function. Mol Cell. 2021;81(18):3691\u2013707.","journal-title":"Mol Cell"},{"key":"570_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101284","volume":"26","author":"L Zhang","year":"2019","unstructured":"Zhang L, Wang X, Cueto R, Effi C, Zhang Y, Tan H, et\u00a0al. Biochemical basis and metabolic interplay of redox regulation. Redox Biol. 2019;26: 101284.","journal-title":"Redox Biol"},{"issue":"1","key":"570_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-022-01313-4","volume":"15","author":"P Jin","year":"2022","unstructured":"Jin P, Jiang J, Zhou L, Huang Z, Nice EC, Huang C, et\u00a0al. Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. J Hematol Oncol. 2022;15(1):97.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"570_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-018-0909-x","volume":"37","author":"H Yang","year":"2018","unstructured":"Yang H, Villani RM, Wang H, Simpson MJ, Roberts MS, Tang M, et\u00a0al. The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res CR. 2018;37(1):266.","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"5","key":"570_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/0008-5472.CAN-19-1920","volume":"80","author":"AJ Robinson","year":"2020","unstructured":"Robinson AJ, Hopkins GL, Rastogi N, Hodges M, Doyle M, Davies S, et\u00a0al. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3. Can Res. 2020;80(5):937\u201349.","journal-title":"Can Res"},{"issue":"22","key":"570_CR14","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1158\/0008-5472.CAN-21-0061","volume":"81","author":"K Sanjiv","year":"2021","unstructured":"Sanjiv K, Calder\u00f3n-Monta\u00f1o JM, Pham TM, Erkers T, Tsuber V, Alml\u00f6f I, et\u00a0al. MTH1 inhibitor TH1579 induces oxidative DNA damage and mitotic arrest in acute myeloid leukemia. Can Res. 2021;81(22):5733\u201344.","journal-title":"Can Res"},{"issue":"20","key":"570_CR15","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/0008-5472.CAN-19-0515","volume":"79","author":"M Hosseini","year":"2019","unstructured":"Hosseini M, Rezvani HR, Aroua N, Bosc C, Farge T, Saland E, et\u00a0al. Targeting myeloperoxidase disrupts mitochondrial redox balance and overcomes cytarabine resistance in human acute myeloid leukemia. Can Res. 2019;79(20):5191\u2013203.","journal-title":"Can Res"},{"issue":"1","key":"570_CR16","first-page":"74","volume":"9","author":"M Romo-Gonz\u00e1lez","year":"2020","unstructured":"Romo-Gonz\u00e1lez M, Moreno-Paz S, Garc\u00eda-Hern\u00e1ndez V, S\u00e1nchez-Guijo F, Hern\u00e1ndez-Hern\u00e1ndez \u00c1. Inhibition of xanthine oxidoreductase enhances the potential of tyrosine kinase inhibitors against chronic myeloid leukemia. Antioxidants (Basel, Switzerland). 2020;9(1):74.","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"570_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103367","volume":"163","author":"CH Kim","year":"2021","unstructured":"Kim CH, Leitch HA. Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae. Crit Rev Oncol Hematol. 2021;163: 103367.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"570_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41580-020-0230-3","volume":"21","author":"H Sies","year":"2020","unstructured":"Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21(7):363\u201383.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"570_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fimmu.2018.00586","volume":"9","author":"IM Rea","year":"2018","unstructured":"Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586.","journal-title":"Front Immunol"},{"key":"570_CR20","doi-asserted-by":"publisher","first-page":"101263","DOI":"10.1016\/j.arr.2021.101263","volume":"67","author":"PA Dionisio","year":"2021","unstructured":"Dionisio PA, Amaral JD, Rodrigues CMP. Oxidative stress and regulated cell death in Parkinson\u2019s disease. Ageing Res Rev. 2021;67:101263.","journal-title":"Ageing Res Rev"},{"issue":"3","key":"570_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20(3):148\u201360.","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"570_CR22","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.tips.2017.04.005","volume":"38","author":"P Poprac","year":"2017","unstructured":"Poprac P, Jomova K, Simunkova M, Kollar V, Rhodes CJ, Valko M. Targeting free radicals in oxidative stress-related human diseases. Trends Pharmacol Sci. 2017;38(7):592\u2013607.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"570_CR23","first-page":"1306","volume":"11","author":"B Miglioranza Scavuzzi","year":"2022","unstructured":"Miglioranza Scavuzzi B, Holoshitz J. Endoplasmic reticulum stress, oxidative stress, and rheumatic diseases. Antioxidants (Basel, Switzerland). 2022;11(7):1306.","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"22","key":"570_CR24","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1093\/eurheartj\/ehq396","volume":"31","author":"T M\u00fcnzel","year":"2010","unstructured":"M\u00fcnzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31(22):2741\u20138.","journal-title":"Eur Heart J"},{"key":"570_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101875","volume":"42","author":"A Daiber","year":"2021","unstructured":"Daiber A, Hahad O, Andreadou I, Steven S, Daub S, M\u00fcnzel T. Redox-related biomarkers in human cardiovascular disease - classical footprints and beyond. Redox Biol. 2021;42: 101875.","journal-title":"Redox Biol"},{"issue":"11","key":"570_CR26","doi-asserted-by":"publisher","first-page":"bqab185","DOI":"10.1210\/endocr\/bqab185","volume":"162","author":"N Sumien","year":"2021","unstructured":"Sumien N, Cunningham JT, Davis DL, Engelland R, Fadeyibi O, Farmer GE, et\u00a0al. Neurodegenerative disease: roles for sex, hormones, and oxidative stress. Endocrinology. 2021;162(11):bqab185.","journal-title":"Endocrinology"},{"key":"570_CR27","doi-asserted-by":"publisher","first-page":"105269","DOI":"10.1016\/j.neuint.2021.105269","volume":"153","author":"E Cecerska-Heryc","year":"2022","unstructured":"Cecerska-Heryc E, Polikowska A, Serwin N, Roszak M, Grygorcewicz B, Heryc R, et\u00a0al. Importance of oxidative stress in the pathogenesis, diagnosis, and monitoring of patients with neuropsychiatric disorders, a review. Neurochem Int. 2022;153:105269.","journal-title":"Neurochem Int"},{"key":"570_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.redox.2018.09.025","volume":"20","author":"T Yuan","year":"2019","unstructured":"Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, et\u00a0al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2019;20:247\u201360.","journal-title":"Redox Biol"},{"issue":"2","key":"570_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","volume":"38","author":"JD Hayes","year":"2020","unstructured":"Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38(2):167\u201397.","journal-title":"Cancer Cell"},{"issue":"17","key":"570_CR30","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1182\/blood-2013-10-532200","volume":"123","author":"R Jitschin","year":"2014","unstructured":"Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J, et\u00a0al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 2014;123(17):2663\u201372.","journal-title":"Blood"},{"key":"570_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13046-014-0106-5","volume":"33","author":"UK Udensi","year":"2014","unstructured":"Udensi UK, Tchounwou PB. Dual effect of oxidative stress on leukemia cancer induction and treatment. J Exp Clin Cancer Res CR. 2014;33:106.","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"24","key":"570_CR32","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1182\/bloodadvances.2019000677","volume":"3","author":"F Picou","year":"2019","unstructured":"Picou F, Vignon C, Debeissat C, Lachot S, Kosmider O, Gallay N, et\u00a0al. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Adv. 2019;3(24):4271\u20139.","journal-title":"Blood Adv"},{"issue":"18","key":"570_CR33","doi-asserted-by":"publisher","first-page":"8798","DOI":"10.1021\/acs.chemrev.7b00698","volume":"118","author":"S Parvez","year":"2018","unstructured":"Parvez S, Long MJC, Poganik JR, Aye Y. Redox signaling by reactive electrophiles and oxidants. Chem Rev. 2018;118(18):8798\u2013888.","journal-title":"Chem Rev"},{"key":"570_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2013.07.036","volume":"66","author":"J Lu","year":"2014","unstructured":"Lu J, Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med. 2014;66:75\u201387.","journal-title":"Free Radic Biol Med"},{"issue":"5782","key":"570_CR35","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1126\/science.1130481","volume":"312","author":"SG Rhee","year":"2006","unstructured":"Rhee SG. H2O2, a necessary evil for cell signaling. Science. 2006;312(5782):1882\u20133.","journal-title":"Science"},{"issue":"8","key":"570_CR36","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.tcb.2021.02.005","volume":"31","author":"A He","year":"2021","unstructured":"He A, Dean JM, Lodhi IJ. Peroxisomes as cellular adaptors to metabolic and environmental stress. Trends Cell Biol. 2021;31(8):656\u201370.","journal-title":"Trends Cell Biol"},{"key":"570_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101084","volume":"25","author":"US Srinivas","year":"2019","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019;25: 101084.","journal-title":"Redox Biol"},{"issue":"6","key":"570_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden BT. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35(6):830\u201349.","journal-title":"Cancer Cell"},{"issue":"10","key":"570_CR39","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.1021\/cr200084z","volume":"111","author":"H Yin","year":"2011","unstructured":"Yin H, Xu L, Porter NA. Free radical lipid peroxidation: mechanisms and analysis. Chem Rev. 2011;111(10):5944\u201372.","journal-title":"Chem Rev"},{"key":"570_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.redox.2015.01.002","volume":"4","author":"H Sies","year":"2015","unstructured":"Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180\u20133.","journal-title":"Redox Biol"},{"issue":"6","key":"570_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.tcb.2020.03.002","volume":"30","author":"IS Harris","year":"2020","unstructured":"Harris IS, DeNicola GM. The complex interplay between antioxidants and ROS in cancer. Trends Cell Biol. 2020;30(6):440\u201351.","journal-title":"Trends Cell Biol"},{"key":"570_CR42","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1146\/annurev-biochem-061516-045037","volume":"86","author":"H Sies","year":"2017","unstructured":"Sies H, Berndt C, Jones DP. Oxidative stress. Annu Rev Biochem. 2017;86:715\u201348.","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"570_CR43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et\u00a0al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52(2):192\u2013203.","journal-title":"Exp Mol Med"},{"key":"570_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s11658-018-0088-y","volume":"23","author":"MV Gwangwa","year":"2018","unstructured":"Gwangwa MV, Joubert AM, Visagie MH. Crosstalk between the Warburg effect, redox regulation and autophagy induction in tumourigenesis. Cell Mol Biol Lett. 2018;23:20.","journal-title":"Cell Mol Biol Lett"},{"key":"570_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121110","volume":"277","author":"B Niu","year":"2021","unstructured":"Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan X, et\u00a0al. Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials. 2021;277: 121110.","journal-title":"Biomaterials"},{"key":"570_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","volume":"41","author":"Q Cui","year":"2018","unstructured":"Cui Q, Wang J-Q, Assaraf YG, Ren L, Gupta P, Wei L, et\u00a0al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updates. 2018;41:1\u201325.","journal-title":"Drug Resist Updates"},{"key":"570_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101975","volume":"43","author":"FT Ogata","year":"2021","unstructured":"Ogata FT, Branco V, Vale FF, Coppo L. Glutaredoxin: discovery, redox defense and much more. Redox Biol. 2021;43: 101975.","journal-title":"Redox Biol"},{"key":"570_CR48","doi-asserted-by":"crossref","unstructured":"Kennedy L, Sandhu JK, Harper M-E, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10(10).","DOI":"10.3390\/biom10101429"},{"issue":"7","key":"570_CR49","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1083\/jcb.201804161","volume":"217","author":"A Bansal","year":"2018","unstructured":"Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018;217(7):2291\u20138.","journal-title":"J Cell Biol"},{"key":"570_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.critrevonc.2018.05.014","volume":"128","author":"CR Corso","year":"2018","unstructured":"Corso CR, Acco A. Glutathione system in animal model of solid tumors: from regulation to therapeutic target. Crit Rev Oncol Hematol. 2018;128:43\u201357.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"570_CR51","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.4252\/wjsc.v12.i11.1410","volume":"12","author":"P Jagust","year":"2020","unstructured":"Jagust P, Alcal\u00e1 S, Sainz B Jr, Heeschen C, Sancho P. Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells. World J Stem Cells. 2020;12(11):1410\u201328.","journal-title":"World J Stem Cells"},{"issue":"3","key":"570_CR52","first-page":"364","volume":"10","author":"M Vairetti","year":"2021","unstructured":"Vairetti M, Di Pasqua LG, Cagna M, Richelmi P, Ferrigno A, Berardo C. Changes in glutathione content in liver diseases: an update. Antioxidants (Basel, Switzerland). 2021;10(3):364.","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"7","key":"570_CR53","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/ijms19071882","volume":"19","author":"SC Nunes","year":"2018","unstructured":"Nunes SC, Serpa J. Glutathione in ovarian cancer: a double-edged sword. Int J Mol Sci. 2018;19(7):1882.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"570_CR54","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1096\/fj.201701157R","volume":"32","author":"T Miran","year":"2018","unstructured":"Miran T, Vogg ATJ, Drude N, Mottaghy FM, Morgenroth A. Modulation of glutathione promotes apoptosis in triple-negative breast cancer cells. FASEB J. 2018;32(5):2803\u201313.","journal-title":"FASEB J"},{"issue":"3","key":"570_CR55","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/0008-5472.CAN-20-0617","volume":"81","author":"W Guo","year":"2021","unstructured":"Guo W, Li K, Sun B, Xu D, Tong L, Yin H, et\u00a0al. Dysregulated glutamate transporter SLC1A1 propels cystine uptake via Xc- for glutathione synthesis in lung cancer. Can Res. 2021;81(3):552\u201366.","journal-title":"Can Res"},{"issue":"9","key":"570_CR56","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3109\/10715762.2015.1035268","volume":"49","author":"AC Goncalves","year":"2015","unstructured":"Goncalves AC, Cortesao E, Oliveiros B, Alves V, Espadana AI, Rito L, et\u00a0al. Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: a pilot study. Free Radic Res. 2015;49(9):1081\u201394.","journal-title":"Free Radic Res"},{"issue":"1","key":"570_CR57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.sjbs.2014.09.002","volume":"22","author":"M Rasool","year":"2015","unstructured":"Rasool M, Farooq S, Malik A, Shaukat A, Manan A, Asif M, et\u00a0al. Assessment of circulating biochemical markers and antioxidative status in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Saudi J Biol Sci. 2015;22(1):106\u201311.","journal-title":"Saudi J Biol Sci"},{"issue":"18","key":"570_CR58","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1182\/blood-2018-10-808873","volume":"133","author":"MD Filippi","year":"2019","unstructured":"Filippi MD, Ghaffari S. Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities. Blood. 2019;133(18):1943\u201352.","journal-title":"Blood"},{"issue":"9","key":"570_CR59","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41580-022-00523-5","volume":"23","author":"L Heinke","year":"2022","unstructured":"Heinke L. Mitochondrial ROS drive cell cycle progression. Nat Rev Mol Cell Biol. 2022;23(9):581.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"570_CR60","first-page":"415","volume":"10","author":"P Hernansanz-Agust\u00edn","year":"2021","unstructured":"Hernansanz-Agust\u00edn P, Enr\u00edquez JA. Generation of reactive oxygen species by mitochondria. Antioxidants (Basel, Switzerland). 2021;10(3):415.","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"6","key":"570_CR61","first-page":"472","volume":"9","author":"RJ Mailloux","year":"2020","unstructured":"Mailloux RJ. An update on mitochondrial reactive oxygen species production. Antioxidants (Basel, Switzerland). 2020;9(6):472.","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"1","key":"570_CR62","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.redox.2013.04.005","volume":"1","author":"CL Quinlan","year":"2013","unstructured":"Quinlan CL, Perevoshchikova IV, Hey-Mogensen M, Orr AL, Brand MD. Sites of reactive oxygen species generation by mitochondria oxidizing different substrates. Redox Biol. 2013;1(1):304\u201312.","journal-title":"Redox Biol"},{"issue":"1\u20132","key":"570_CR63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10555-019-09789-2","volume":"38","author":"VL Payen","year":"2019","unstructured":"Payen VL, Zampieri LX, Porporato PE, Sonveaux P. Pro- and antitumor effects of mitochondrial reactive oxygen species. Cancer Metastasis Rev. 2019;38(1\u20132):189\u2013203.","journal-title":"Cancer Metastasis Rev"},{"key":"570_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2014.10.511","volume":"78","author":"L Bleier","year":"2015","unstructured":"Bleier L, Wittig I, Heide H, Steger M, Brandt U, Droese S. Generator-specific targets of mitochondrial reactive oxygen species. Free Radical Biol Med. 2015;78:1\u201310.","journal-title":"Free Radical Biol Med"},{"key":"570_CR65","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.freeradbiomed.2016.04.001","volume":"100","author":"MD Brand","year":"2016","unstructured":"Brand MD. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. Free Radical Biol Med. 2016;100:14\u201331.","journal-title":"Free Radical Biol Med"},{"issue":"4","key":"570_CR66","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/sj.cdd.4402307","volume":"15","author":"T Klimova","year":"2008","unstructured":"Klimova T, Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ. 2008;15(4):660\u20136.","journal-title":"Cell Death Differ"},{"key":"570_CR67","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.freeradbiomed.2016.04.198","volume":"100","author":"L Diebold","year":"2016","unstructured":"Diebold L, Chandel NS. Mitochondrial ROS regulation of proliferating cells. Free Radical Biol Med. 2016;100:86\u201393.","journal-title":"Free Radical Biol Med"},{"key":"570_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.freeradbiomed.2020.02.029","volume":"152","author":"J Yan","year":"2020","unstructured":"Yan J, Jiang J, He L, Chen L. Mitochondrial superoxide\/hydrogen peroxide: an emerging therapeutic target for metabolic diseases. Free Radical Biol Med. 2020;152:33\u201342.","journal-title":"Free Radical Biol Med"},{"issue":"3","key":"570_CR69","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/cr.2017.155","volume":"28","author":"PE Porporato","year":"2018","unstructured":"Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265\u201380.","journal-title":"Cell Res"},{"key":"570_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.377","volume":"7","author":"Q Le","year":"2016","unstructured":"Le Q, Yao W, Chen Y, Yan B, Liu C, Yuan M, et\u00a0al. GRK6 regulates ROS response and maintains hematopoietic stem cell self-renewal. Cell Death Dis. 2016;7: e2478.","journal-title":"Cell Death Dis"},{"issue":"7011","key":"570_CR71","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/nature02989","volume":"431","author":"K Ito","year":"2004","unstructured":"Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, et\u00a0al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004;431(7011):997\u20131002.","journal-title":"Nature"},{"issue":"10","key":"570_CR72","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/10245332.2016.1165446","volume":"21","author":"Y Cao","year":"2016","unstructured":"Cao Y, Fang Y, Cai J, Li X, Xu F, Yuan N, et\u00a0al. ROS functions as an upstream trigger for autophagy to drive hematopoietic stem cell differentiation. Hematology. 2016;21(10):613\u20138.","journal-title":"Hematology"},{"issue":"3","key":"570_CR73","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.stem.2021.02.011","volume":"28","author":"RP Chakrabarty","year":"2021","unstructured":"Chakrabarty RP, Chandel NS. Mitochondria as signaling organelles control mammalian stem cell fate. Cell Stem Cell. 2021;28(3):394\u2013408.","journal-title":"Cell Stem Cell"},{"issue":"20","key":"570_CR74","doi-asserted-by":"publisher","first-page":"11117","DOI":"10.3390\/ijms222011117","volume":"22","author":"C Morganti","year":"2021","unstructured":"Morganti C, Ito K. Mitochondrial contributions to hematopoietic stem cell aging. Int J Mol Sci. 2021;22(20):11117.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"570_CR75","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41423-022-00858-1","volume":"19","author":"R Begum","year":"2022","unstructured":"Begum R, Thota S, Abdulkadir A, Kaur G, Bagam P, Batra S. NADPH oxidase family proteins: signaling dynamics to disease management. Cell Mol Immunol. 2022;19(6):660\u201386.","journal-title":"Cell Mol Immunol"},{"key":"570_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102298","volume":"52","author":"BC Ogboo","year":"2022","unstructured":"Ogboo BC, Grabovyy UV, Maini A, Scouten S, van der Vliet A, Mattevi A, et\u00a0al. Architecture of the NADPH oxidase family of enzymes. Redox Biol. 2022;52: 102298.","journal-title":"Redox Biol"},{"issue":"6","key":"570_CR77","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/antiox10060890","volume":"10","author":"A Vermot","year":"2021","unstructured":"Vermot A, Petit-Hartlein I, Smith SME, Fieschi F. NADPH oxidases (NOX): an overview from discovery, molecular mechanisms to physiology and pathology. Antioxidants (Basel). 2021;10(6):890.","journal-title":"Antioxidants (Basel)"},{"issue":"3","key":"570_CR78","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.freeradbiomed.2007.03.028","volume":"43","author":"JD Lambeth","year":"2007","unstructured":"Lambeth JD, Kawahara T, Diebold B. Regulation of Nox and Duox enzymatic activity and expression. Free Radical Biol Med. 2007;43(3):319\u201331.","journal-title":"Free Radical Biol Med"},{"issue":"1","key":"570_CR79","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1152\/physrev.00044.2005","volume":"87","author":"K Bedard","year":"2007","unstructured":"Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87(1):245\u2013313.","journal-title":"Physiol Rev"},{"issue":"3","key":"570_CR80","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1089\/ars.2017.7268","volume":"30","author":"A Parascandolo","year":"2019","unstructured":"Parascandolo A, Laukkanen MO. Carcinogenesis and reactive oxygen species signaling: interaction of the NADPH oxidase NOX1-5 and superoxide dismutase 1\u20133 signal transduction pathways. Antioxid Redox Signal. 2019;30(3):443\u201386.","journal-title":"Antioxid Redox Signal"},{"key":"570_CR81","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fncel.2016.00301","volume":"10","author":"R Rastogi","year":"2017","unstructured":"Rastogi R, Geng X, Li F, Ding Y. NOX activation by subunit interaction and underlying mechanisms in disease. Front Cell Neurosci. 2017;10:301.","journal-title":"Front Cell Neurosci"},{"key":"570_CR82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.freeradbiomed.2017.03.017","volume":"109","author":"K Schroeder","year":"2017","unstructured":"Schroeder K, Weissmann N, Brandes RP. Organizers and activators: cytosolic Nox proteins impacting on vascular function. Free Radical Biol Med. 2017;109:22\u201332.","journal-title":"Free Radical Biol Med"},{"key":"570_CR83","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4590127","author":"G Giardino","year":"2017","unstructured":"Giardino G, Cicalese MP, Delmonte O, Migliavacca M, Palterer B, Loffredo L, et\u00a0al. NADPH oxidase deficiency: a multisystem approach. Oxid Med Cell Longev. 2017. https:\/\/doi.org\/10.1155\/2017\/4590127.","journal-title":"Oxid Med Cell Longev"},{"issue":"26","key":"570_CR84","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1073\/pnas.1702293114","volume":"114","author":"F Magnani","year":"2017","unstructured":"Magnani F, Nenci S, Fananas EM, Ceccon M, Romero E, Fraaije MW, et\u00a0al. Crystal structures and atomic model of NADPH oxidase. Proc Natl Acad Sci USA. 2017;114(26):6764\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"570_CR85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.critrevonc.2011.03.005","volume":"81","author":"JL Sardina","year":"2012","unstructured":"Sardina JL, Lopez-Ruano G, Sanchez-Sanchez B, Llanillo M, Hernandez-Hernandez A. Reactive oxygen species: are they important for haematopoiesis? Crit Rev Oncol Hematol. 2012;81(3):257\u201374.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"570_CR86","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1182\/blood.V93.9.2928.409k25_2928_2935","volume":"93","author":"M Sattler","year":"1999","unstructured":"Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, et\u00a0al. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999;93(9):2928\u201335.","journal-title":"Blood"},{"issue":"19","key":"570_CR87","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2013-04-491944","volume":"122","author":"PS Hole","year":"2013","unstructured":"Hole PS, Zabkiewicz J, Munje C, Newton Z, Pearn L, White P, et\u00a0al. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood. 2013;122(19):3322\u201330.","journal-title":"Blood"},{"issue":"8","key":"570_CR88","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s00432-022-03986-3","volume":"148","author":"MB Demircan","year":"2022","unstructured":"Demircan MB, Schnoeder TM, Mgbecheta PC, Schroeder K, Boehmer F-D, Heidel FH. Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML). J Cancer Res Clin Oncol. 2022;148(8):1983\u201390.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"570_CR89","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/ijo.2014.2706","volume":"46","author":"E Agostinelli","year":"2015","unstructured":"Agostinelli E, Vianello F, Magliulo G, Thomas T, Thomas TJ. Nanoparticle strategies for cancer therapeutics: nucleic acids, polyamines, bovine serum amine oxidase and iron oxide nanoparticles. Int J Oncol. 2015;46(1):5\u201316.","journal-title":"Int J Oncol"},{"issue":"5","key":"570_CR90","doi-asserted-by":"publisher","first-page":"E827","DOI":"10.1152\/ajpendo.00378.2020","volume":"319","author":"M Furuhashi","year":"2020","unstructured":"Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 2020;319(5):E827\u201334.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"570_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101882","volume":"41","author":"M Bortolotti","year":"2021","unstructured":"Bortolotti M, Polito L, Battelli MG, Bolognesi A. Xanthine oxidoreductase: one enzyme for multiple physiological tasks. Redox Biol. 2021;41: 101882.","journal-title":"Redox Biol"},{"key":"570_CR92","doi-asserted-by":"publisher","first-page":"3527579","DOI":"10.1155\/2016\/3527579","volume":"2016","author":"MG Battelli","year":"2016","unstructured":"Battelli MG, Polito L, Bortolotti M, Bolognesi A. Xanthine oxidoreductase-derived reactive species: physiological and pathological effects. Oxid Med Cell Longev. 2016;2016:3527579.","journal-title":"Oxid Med Cell Longev"},{"key":"570_CR93","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1038\/srep06307","volume":"4","author":"M Abooali","year":"2014","unstructured":"Abooali M, Lall GS, Coughlan K, Lall HS, Gibbs BF, Sumbayev VV. Crucial involvement of xanthine oxidase in the intracellular signalling networks associated with human myeloid cell function. Sci Rep. 2014;4:6307.","journal-title":"Sci Rep"},{"issue":"12","key":"570_CR94","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.3324\/haematol.2018.202275","volume":"104","author":"T Raskovalova","year":"2019","unstructured":"Raskovalova T, Berger MG, Jacob MC, Park S, Campos L, Aanei CM, et\u00a0al. Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes: a diagnostic accuracy study. Haematologica. 2019;104(12):2382\u201390.","journal-title":"Haematologica"},{"issue":"17","key":"570_CR95","doi-asserted-by":"publisher","first-page":"7915","DOI":"10.1073\/pnas.90.17.7915","volume":"90","author":"BN Ames","year":"1993","unstructured":"Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA. 1993;90(17):7915\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"570_CR96","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2174\/1389200215666141125121659","volume":"15","author":"S Bhattacharyya","year":"2014","unstructured":"Bhattacharyya S, Sinha K, Sil PC. Cytochrome P450s: mechanisms and biological implications in drug metabolism and its interaction with oxidative stress. Curr Drug Metab. 2014;15(7):719\u201342.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"570_CR97","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.blre.2017.08.005","volume":"32","author":"F Pilo","year":"2018","unstructured":"Pilo F, Angelucci E. A storm in the niche: iron, oxidative stress and haemopoiesis. Blood Rev. 2018;32(1):29\u201335.","journal-title":"Blood Rev"},{"issue":"4","key":"570_CR98","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.immuni.2018.03.024","volume":"48","author":"Q Wei","year":"2018","unstructured":"Wei Q, Frenette PS. Niches for hematopoietic stem cells and their progeny. Immunity. 2018;48(4):632\u201348.","journal-title":"Immunity"},{"issue":"5","key":"570_CR99","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41580-019-0103-9","volume":"20","author":"S Pinho","year":"2019","unstructured":"Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche. Nat Rev Mol Cell Biol. 2019;20(5):303\u201320.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7689","key":"570_CR100","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature25022","volume":"553","author":"E Laurenti","year":"2018","unstructured":"Laurenti E, Gottgens B. From haematopoietic stem cells to complex differentiation landscapes. Nature. 2018;553(7689):418\u201326.","journal-title":"Nature"},{"issue":"7473","key":"570_CR101","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nature12612","volume":"502","author":"Y Kunisaki","year":"2013","unstructured":"Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et\u00a0al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature. 2013;502(7473):637.","journal-title":"Nature"},{"issue":"9","key":"570_CR102","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nri.2017.53","volume":"17","author":"GM Crane","year":"2017","unstructured":"Crane GM, Jeffery E, Morrison SJ. Adult haematopoietic stem cell niches. Nat Rev Immunol. 2017;17(9):573\u201390.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"570_CR103","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.bbagen.2014.11.010","volume":"1850","author":"Z-W Ye","year":"2015","unstructured":"Ye Z-W, Zhang J, Townsend DM, Tew KD. Oxidative stress, redox regulation and diseases of cellular differentiation. BBA-Gen Subjects. 2015;1850(8):1607\u201321.","journal-title":"BBA-Gen Subjects"},{"issue":"11","key":"570_CR104","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nm.3707","volume":"20","author":"I Bruns","year":"2014","unstructured":"Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki Y, et\u00a0al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med. 2014;20(11):1315\u201320.","journal-title":"Nat Med"},{"issue":"7382","key":"570_CR105","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature10783","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481(7382):457-U65.","journal-title":"Nature"},{"issue":"7440","key":"570_CR106","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature11926","volume":"495","author":"A Greenbaum","year":"2013","unstructured":"Greenbaum A, Hsu YMS, Day RB, Schuettpelz LG, Christopher MJ, Borgerding JN, et\u00a0al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495(7440):227\u201330.","journal-title":"Nature"},{"issue":"3","key":"570_CR107","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.stem.2018.07.003","volume":"23","author":"HA Himburg","year":"2018","unstructured":"Himburg HA, Termini CM, Schlussel L, Kan J, Li M, Zhao L, et\u00a0al. Distinct bone marrow sources of pleiotrophin control hematopoietic stem cell maintenance and regeneration. Cell Stem Cell. 2018;23(3):370.","journal-title":"Cell Stem Cell"},{"issue":"8","key":"570_CR108","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/ncb3570","volume":"19","author":"BO Zhou","year":"2017","unstructured":"Zhou BO, Yu H, Yue R, Zhao Z, Rios JJ, Naveiras O, et\u00a0al. Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. Nat Cell Biol. 2017;19(8):891.","journal-title":"Nat Cell Biol"},{"issue":"7483","key":"570_CR109","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","volume":"505","author":"SJ Morrison","year":"2014","unstructured":"Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505(7483):327\u201334.","journal-title":"Nature"},{"issue":"8","key":"570_CR110","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1182\/blood-2007-05-087759","volume":"110","author":"Y-Y Jang","year":"2007","unstructured":"Jang Y-Y, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood. 2007;110(8):3056\u201363.","journal-title":"Blood"},{"issue":"11","key":"570_CR111","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1089\/ars.2014.5941","volume":"21","author":"A Ludin","year":"2014","unstructured":"Ludin A, Gur-Cohen S, Golan K, Kaufmann KB, Itkin T, Medaglia C, et\u00a0al. Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal. 2014;21(11):1605\u201319.","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"570_CR112","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.cell.2008.10.048","volume":"135","author":"A Wilson","year":"2008","unstructured":"Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, et\u00a0al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118\u201329.","journal-title":"Cell"},{"issue":"2","key":"570_CR113","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cell.2007.01.003","volume":"128","author":"Z Tothova","year":"2007","unstructured":"Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, et\u00a0al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007;128(2):325\u201339.","journal-title":"Cell"},{"issue":"8","key":"570_CR114","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood-2009-03-209734","volume":"114","author":"A Rizo","year":"2009","unstructured":"Rizo A, Olthof S, Han L, Vellenga E, de Haan G, Schuringa JJ. Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood. 2009;114(8):1498\u2013505.","journal-title":"Blood"},{"issue":"1","key":"570_CR115","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.stem.2007.02.001","volume":"1","author":"K Miyamoto","year":"2007","unstructured":"Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, Yamazaki S, et\u00a0al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell. 2007;1(1):101\u201312.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"570_CR116","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/MOH.0000000000000441","volume":"25","author":"V Menon","year":"2018","unstructured":"Menon V, Ghaffari S. Transcription factors FOXO in the regulation of homeostatic hematopoiesis. Curr Opin Hematol. 2018;25(4):290\u20138.","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"570_CR117","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1182\/blood-2008-05-159848","volume":"112","author":"K Miyamoto","year":"2008","unstructured":"Miyamoto K, Miyamoto T, Kato R, Yoshimura A, Motoyama N, Suda T. FoxO3a regulates hematopoietic homeostasis through a negative feedback pathway in conditions of stress or aging. Blood. 2008;112(12):4485\u201393.","journal-title":"Blood"},{"issue":"24","key":"570_CR118","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1038\/emboj.2010.292","volume":"29","author":"S Yalcin","year":"2010","unstructured":"Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, Sellers R, et\u00a0al. ROS-mediated amplification of AKT\/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-\/-) mice. EMBO J. 2010;29(24):4118\u201331.","journal-title":"EMBO J"},{"issue":"9","key":"570_CR119","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.15252\/embr.201439704","volume":"16","author":"P Rimmele","year":"2015","unstructured":"Rimmele P, Liang R, Bigarella CL, Kocabas F, Xie JJ, Serasinghe MN, et\u00a0al. Mitochondrial metabolism in hematopoietic stem cells requires functional FOXO3. EMBO Rep. 2015;16(9):1164\u201376.","journal-title":"EMBO Rep"},{"issue":"6","key":"570_CR120","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/cdd.2011.179","volume":"19","author":"EC Ferber","year":"2012","unstructured":"Ferber EC, Peck B, Delpuech O, Bell GP, East P, Schulze A. FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ. 2012;19(6):968\u201379.","journal-title":"Cell Death Differ"},{"issue":"19","key":"570_CR121","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1038\/emboj.2013.186","volume":"32","author":"H Yeo","year":"2013","unstructured":"Yeo H, Lyssiotis CA, Zhang YQ, Ying HQ, Asara JM, Cantley LC, et\u00a0al. FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO J. 2013;32(19):2589\u2013602.","journal-title":"EMBO J"},{"issue":"3","key":"570_CR122","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.stem.2010.07.011","volume":"7","author":"T Simsek","year":"2010","unstructured":"Simsek T, Kocabas F, Zheng JK, DeBerardinis RJ, Mahmoud AI, Olson EN, et\u00a0al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell. 2010;7(3):380\u201390.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"570_CR123","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.stem.2012.10.011","volume":"12","author":"K Takubo","year":"2013","unstructured":"Takubo K, Nagamatsu G, Kobayashi CI, Nakamura-Ishizu A, Kobayashi H, Ikeda E, et\u00a0al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell. 2013;12(1):49\u201361.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"570_CR124","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1182\/blood-2005-12-4995","volume":"107","author":"RD Unwin","year":"2006","unstructured":"Unwin RD, Smith DL, Blinco D, Wilson CL, Miller CJ, Evans CA, et\u00a0al. Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood. 2006;107(12):4687\u201394.","journal-title":"Blood"},{"issue":"5","key":"570_CR125","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/ncb2468","volume":"14","author":"M Maryanovich","year":"2012","unstructured":"Maryanovich M, Oberkovitz G, Niv H, Vorobiyov L, Zaltsman Y, Brenner O, et\u00a0al. The ATM-BID pathway regulates quiescence and survival of haematopoietic stem cells. Nat Cell Biol. 2012;14(5):535-U185.","journal-title":"Nat Cell Biol"},{"key":"570_CR126","doi-asserted-by":"publisher","first-page":"7901","DOI":"10.1038\/ncomms8901","volume":"6","author":"M Maryanovich","year":"2015","unstructured":"Maryanovich M, Zaltsman Y, Ruggiero A, Goldman A, Shachnai L, Zaidman SL, et\u00a0al. An MTCH2 pathway repressing mitochondria metabolism regulates haematopoietic stem cell fate. Nat Commun. 2015;6:7901.","journal-title":"Nat Commun"},{"issue":"1","key":"570_CR127","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2013-06-508333","volume":"123","author":"I Tai-Nagara","year":"2014","unstructured":"Tai-Nagara I, Matsuoka S, Ariga H, Suda T. Mortalin and DJ-1 coordinately regulate hematopoietic stem cell function through the control of oxidative stress. Blood. 2014;123(1):41\u201350.","journal-title":"Blood"},{"issue":"10","key":"570_CR128","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1084\/jem.20081297","volume":"205","author":"C Chen","year":"2008","unstructured":"Chen C, Liu Y, Liu RH, Ikenoue T, Guan KL, Liu Y, et\u00a0al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med. 2008;205(10):2397\u2013408.","journal-title":"J Exp Med"},{"issue":"14","key":"570_CR129","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358\u201374.","journal-title":"N Engl J Med"},{"issue":"20","key":"570_CR130","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"7","key":"570_CR131","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","volume":"128","author":"M Pfeilst\u00f6cker","year":"2016","unstructured":"Pfeilst\u00f6cker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sol\u00e9 F, et\u00a0al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902\u201310.","journal-title":"Blood"},{"issue":"7","key":"570_CR132","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et\u00a0al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"11","key":"570_CR133","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et\u00a0al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"key":"570_CR134","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"The ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium","year":"2020","unstructured":"The ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578:82\u201393. https:\/\/doi.org\/10.1038\/s41586-020-1969-6.","journal-title":"Nature"},{"issue":"10","key":"570_CR135","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM197103112841027","volume":"381","author":"RI Henkin","year":"2019","unstructured":"Henkin RI. Clinical and therapeutic implications of cancer stem cells. N Engl J Med. 2019;381(10): e19.","journal-title":"N Engl J Med"},{"issue":"26","key":"570_CR136","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et\u00a0al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496\u2013506.","journal-title":"N Engl J Med"},{"issue":"7367","key":"570_CR137","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et\u00a0al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64\u20139.","journal-title":"Nature"},{"issue":"22","key":"570_CR138","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et\u00a0al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616\u201327.","journal-title":"Blood"},{"issue":"2","key":"570_CR139","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et\u00a0al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241\u20137.","journal-title":"Leukemia"},{"issue":"3","key":"570_CR140","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nm.4047","volume":"22","author":"RK Schneider","year":"2016","unstructured":"Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, et\u00a0al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016;22(3):288\u201397.","journal-title":"Nat Med"},{"issue":"4","key":"570_CR141","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","volume":"26","author":"RK Schneider","year":"2014","unstructured":"Schneider RK, Adem\u00e0 V, Heckl D, J\u00e4r\u00e5s M, Mallo M, Lord AM, et\u00a0al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014;26(4):509\u201320.","journal-title":"Cancer Cell"},{"issue":"7559","key":"570_CR142","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et\u00a0al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature. 2015;523(7559):183\u20138.","journal-title":"Nature"},{"issue":"3","key":"570_CR143","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrc3895","volume":"15","author":"L Yang","year":"2015","unstructured":"Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15(3):152\u201365.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"570_CR144","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/blood-2017-04-777029","volume":"130","author":"M Buscarlet","year":"2017","unstructured":"Buscarlet M, Provost S, Zada YF, Barhdadi A, Bourgoin V, L\u00e9pine G, et\u00a0al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130(6):753\u201362.","journal-title":"Blood"},{"issue":"1","key":"570_CR145","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et\u00a0al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11\u201324.","journal-title":"Cancer Cell"},{"issue":"5","key":"570_CR146","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/leu.2015.358","volume":"30","author":"OA Guryanova","year":"2016","unstructured":"Guryanova OA, Lieu YK, Garrett-Bakelman FE, Spitzer B, Glass JL, Shank K, et\u00a0al. Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia. 2016;30(5):1133\u201342.","journal-title":"Leukemia"},{"issue":"2","key":"570_CR147","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","volume":"126","author":"L Malcovati","year":"2015","unstructured":"Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, J\u00e4dersten M, Jansson M, et\u00a0al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126(2):233\u201341.","journal-title":"Blood"},{"issue":"2","key":"570_CR148","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, et\u00a0al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the prognosis of MDS. Blood. 2020;136(2):157\u201370.","journal-title":"Blood"},{"issue":"7","key":"570_CR149","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/bloodadvances.2019001127","volume":"4","author":"WB Dalton","year":"2020","unstructured":"Dalton WB, Helmenstine E, Pieterse L, Li B, Gocke CD, Donaldson J, et\u00a0al. The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Adv. 2020;4(7):1192\u20136.","journal-title":"Blood Adv"},{"issue":"11","key":"570_CR150","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.20.01659","volume":"39","author":"M Bersanelli","year":"2021","unstructured":"Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, et\u00a0al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol. 2021;39(11):1223\u201333.","journal-title":"J Clin Oncol"},{"issue":"1","key":"570_CR151","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1038\/s41467-018-06063-x","volume":"9","author":"Y Shiozawa","year":"2018","unstructured":"Shiozawa Y, Malcovati L, Gall\u00ec A, Sato-Otsubo A, Kataoka K, Sato Y, et\u00a0al. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nat Commun. 2018;9(1):3649.","journal-title":"Nat Commun"},{"issue":"12","key":"570_CR152","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","volume":"132","author":"A Pellagatti","year":"2018","unstructured":"Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, et\u00a0al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations. Blood. 2018;132(12):1225\u201340.","journal-title":"Blood"},{"issue":"500","key":"570_CR153","doi-asserted-by":"publisher","first-page":"eaav5467","DOI":"10.1126\/scitranslmed.aav5467","volume":"11","author":"S Bondu","year":"2019","unstructured":"Bondu S, Alary A-S, Lef\u00e8vre C, Houy A, Jung G, Lefebvre T, et\u00a0al. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med. 2019;11(500):eaav5467.","journal-title":"Sci Transl Med"},{"issue":"15","key":"570_CR154","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","volume":"119","author":"F Thol","year":"2012","unstructured":"Thol F, Kade S, Schlarmann C, L\u00f6ffeld P, Morgan M, Krauter J, et\u00a0al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578\u201384.","journal-title":"Blood"},{"issue":"25","key":"570_CR155","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","volume":"122","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(25):4021\u201334.","journal-title":"Blood"},{"issue":"3","key":"570_CR156","doi-asserted-by":"publisher","first-page":"300060519891013","DOI":"10.1177\/0300060519891013","volume":"48","author":"B Li","year":"2020","unstructured":"Li B, Zou D, Yang S, Ouyang G, Mu Q. Prognostic significance of U2AF1 mutations in myelodysplastic syndromes: a meta-analysis. J Int Med Res. 2020;48(3):300060519891013.","journal-title":"J Int Med Res"},{"issue":"4","key":"570_CR157","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/annonc\/mdw013","volume":"27","author":"L Dang","year":"2016","unstructured":"Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27(4):599\u2013608.","journal-title":"Ann Oncol"},{"issue":"2","key":"570_CR158","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ng.3742","volume":"49","author":"H Makishima","year":"2017","unstructured":"Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, et\u00a0al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49(2):204\u201312.","journal-title":"Nat Genet"},{"issue":"1","key":"570_CR159","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ajh.24253","volume":"91","author":"N Gangat","year":"2016","unstructured":"Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91(1):76\u201389.","journal-title":"Am J Hematol"},{"issue":"5","key":"570_CR160","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SCW, Ramakrishnan A, et\u00a0al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27(5):617\u201330.","journal-title":"Cancer Cell"},{"issue":"3","key":"570_CR161","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.molcel.2017.12.029","volume":"69","author":"L Chen","year":"2018","unstructured":"Chen L, Chen J-Y, Huang Y-J, Gu Y, Qiu J, Qian H, et\u00a0al. The augmented R-Loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations. Mol Cell. 2018;69(3):412\u201325.","journal-title":"Mol Cell"},{"issue":"7777","key":"570_CR162","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-019-1618-0","volume":"574","author":"A Yoshimi","year":"2019","unstructured":"Yoshimi A, Lin K-T, Wiseman DH, Rahman MA, Pastore A, Wang B, et\u00a0al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574(7777):273\u20137.","journal-title":"Nature"},{"issue":"4","key":"570_CR163","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","volume":"7","author":"EM Stein","year":"2020","unstructured":"Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, et\u00a0al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020;7(4):e309\u201319.","journal-title":"Lancet Haematol"},{"key":"570_CR164","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cbi.2017.12.024","volume":"281","author":"AR Phull","year":"2018","unstructured":"Phull AR, Nasir B, Ul Haq I, Kim SJ. Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid arthritis. Chem Biol Interact. 2018;281:121\u201336.","journal-title":"Chem Biol Interact"},{"key":"570_CR165","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.mam.2018.03.002","volume":"63","author":"CD Ochoa","year":"2018","unstructured":"Ochoa CD, Wu RF, Terada LS. ROS signaling and ER stress in cardiovascular disease. Mol Aspects Med. 2018;63:18\u201329.","journal-title":"Mol Aspects Med"},{"key":"570_CR166","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.redox.2016.08.015","volume":"9","author":"CH Byon","year":"2016","unstructured":"Byon CH, Heath JM, Chen Y. Redox signaling in cardiovascular pathophysiology: a focus on hydrogen peroxide and vascular smooth muscle cells. Redox Biol. 2016;9:244\u201353.","journal-title":"Redox Biol"},{"issue":"6","key":"570_CR167","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/CIRCRESAHA.117.311401","volume":"122","author":"SJ Forrester","year":"2018","unstructured":"Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive oxygen species in metabolic and inflammatory signaling. Circ Res. 2018;122(6):877\u2013902.","journal-title":"Circ Res"},{"key":"570_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101664","volume":"79","author":"M Ruiss","year":"2022","unstructured":"Ruiss M, Findl O, Kronschl\u00e4ger M. The human lens: an antioxidant-dependent tissue revealed by the role of caffeine. Ageing Res Rev. 2022;79: 101664.","journal-title":"Ageing Res Rev"},{"issue":"3","key":"570_CR169","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1046\/j.1365-2141.1997.4373247.x","volume":"99","author":"CM Peddie","year":"1997","unstructured":"Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol. 1997;99(3):625\u201331.","journal-title":"Br J Haematol"},{"issue":"2","key":"570_CR170","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.leukres.2008.07.005","volume":"33","author":"B Novotna","year":"2009","unstructured":"Novotna B, Bagryantseva Y, Siskova M, Neuwirtova R. Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome. Leuk Res. 2009;33(2):340\u20133.","journal-title":"Leuk Res"},{"issue":"9","key":"570_CR171","first-page":"1070","volume":"88","author":"D Bowen","year":"2003","unstructured":"Bowen D, Wang L, Frew M, Kerr R, Groves M. Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: further evidence of a pathogenetic role for oxidative stress? Haematologica. 2003;88(9):1070\u20132.","journal-title":"Haematologica"},{"key":"570_CR172","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fonc.2016.00151","volume":"6","author":"DA Sallman","year":"2016","unstructured":"Sallman DA, Cluzeau T, Basiorka AA, List A. Unraveling the pathogenesis of MDS: the NLRP3 inflammasome and pyroptosis drive the MDS phenotype. Front Oncol. 2016;6:151.","journal-title":"Front Oncol"},{"key":"570_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.586530","volume":"10","author":"E Grignano","year":"2020","unstructured":"Grignano E, Birsen R, Chapuis N, Bouscary D. From iron chelation to overload as a therapeutic strategy to induce ferroptosis in leukemic cells. Front Oncol. 2020;10: 586530.","journal-title":"Front Oncol"},{"issue":"3","key":"570_CR174","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41375-019-0623-5","volume":"34","author":"G Montalban-Bravo","year":"2020","unstructured":"Montalban-Bravo G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, et\u00a0al. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia. 2020;34(3):872\u201381.","journal-title":"Leukemia"},{"issue":"10","key":"570_CR175","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","volume":"133","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133(10):1039\u201348.","journal-title":"Blood"},{"issue":"25","key":"570_CR176","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","volume":"128","author":"AA Basiorka","year":"2016","unstructured":"Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, et\u00a0al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016;128(25):2960\u201375.","journal-title":"Blood"},{"issue":"12","key":"570_CR177","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.3324\/haematol.2016.158857","volume":"102","author":"T Cluzeau","year":"2017","unstructured":"Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, et\u00a0al. Pro-inflammatory proteins S100A9 and tumor necrosis factor-\u03b1 suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica. 2017;102(12):2015\u201320.","journal-title":"Haematologica"},{"issue":"4","key":"570_CR178","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/leu.2017.326","volume":"32","author":"Y Mei","year":"2018","unstructured":"Mei Y, Zhao B, Basiorka AA, Yang J, Cao L, Zhang J, et\u00a0al. Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS. Leukemia. 2018;32(4):1023\u201333.","journal-title":"Leukemia"},{"key":"570_CR179","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3389\/fonc.2020.01656","volume":"10","author":"Q Lv","year":"2020","unstructured":"Lv Q, Niu H, Yue L, Liu J, Yang L, Liu C, et\u00a0al. Abnormal ferroptosis in myelodysplastic syndrome. Front Oncol. 2020;10:1656.","journal-title":"Front Oncol"},{"key":"570_CR180","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2019.07.015","volume":"66","author":"DP Panigrahi","year":"2020","unstructured":"Panigrahi DP, Praharaj PP, Bhol CS, Mahapatra KK, Patra S, Behera BP, et\u00a0al. The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics. Semin Cancer Biol. 2020;66:45\u201358.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"570_CR181","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/leu.2008.389","volume":"23","author":"EJ Houwerzijl","year":"2009","unstructured":"Houwerzijl EJ, Pol HWD, Blom NR, van der Want JJL, de Wolf JTM, Vellenga E. Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria. Leukemia. 2009;23(5):886\u201391.","journal-title":"Leukemia"},{"issue":"4","key":"570_CR182","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/BF02982641","volume":"77","author":"MJ Farquhar","year":"2003","unstructured":"Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol. 2003;77(4):342\u201350.","journal-title":"Int J Hematol"},{"issue":"3","key":"570_CR183","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1084\/jem.20101145","volume":"208","author":"M Mortensen","year":"2011","unstructured":"Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E, et\u00a0al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med. 2011;208(3):455\u201367.","journal-title":"J Exp Med"},{"issue":"6","key":"570_CR184","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/stem.2347","volume":"34","author":"MC Gomez-Puerto","year":"2016","unstructured":"Gomez-Puerto MC, Folkerts H, Wierenga ATJ, Schepers K, Schuringa JJ, Coffer PJ, et\u00a0al. Autophagy proteins ATG5 and ATG7 are essential for the maintenance of human CD34(+) hematopoietic stem-progenitor cells. Stem Cells. 2016;34(6):1651\u201363.","journal-title":"Stem Cells"},{"key":"570_CR185","doi-asserted-by":"publisher","first-page":"6328051","DOI":"10.1155\/2018\/6328051","volume":"2018","author":"H Jiang","year":"2018","unstructured":"Jiang H, Yang L, Guo L, Cui N, Zhang G, Liu C, et\u00a0al. Impaired mitophagy of nucleated erythroid cells leads to anemia in patients with myelodysplastic syndromes. Oxid Med Cell Longev. 2018;2018:6328051.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"570_CR186","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/2159-8290.CD-21-0032","volume":"12","author":"Y Aoyagi","year":"2022","unstructured":"Aoyagi Y, Hayashi Y, Harada Y, Choi K, Matsunuma N, Sadato D, et\u00a0al. Mitochondrial fragmentation triggers ineffective hematopoiesis in myelodysplastic syndromes. Cancer Discov. 2022;12(1):250\u201369.","journal-title":"Cancer Discov"},{"issue":"7","key":"570_CR187","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41568-021-00358-w","volume":"21","author":"PK Kopinski","year":"2021","unstructured":"Kopinski PK, Singh LN, Zhang S, Lott MT, Wallace DC. Mitochondrial DNA variation and cancer. Nat Rev Cancer. 2021;21(7):431\u201345.","journal-title":"Nat Rev Cancer"},{"key":"570_CR188","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.exphem.2021.09.004","volume":"103","author":"J Zou","year":"2021","unstructured":"Zou J, Shi Q, Chen H, Juskevicius R, Zinkel SS. Programmed necroptosis is upregulated in low-grade myelodysplastic syndromes and may play a role in the pathogenesis. Exp Hematol. 2021;103:60\u201372.","journal-title":"Exp Hematol"},{"issue":"6","key":"570_CR189","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000314","volume":"3","author":"U Germing","year":"2019","unstructured":"Germing U, Oliva EN, Hiwase D, Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. Hemasphere. 2019;3(6): e314.","journal-title":"Hemasphere"},{"key":"570_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100689","volume":"45","author":"E Scalzulli","year":"2021","unstructured":"Scalzulli E, Pepe S, Colafigli G, Breccia M. Therapeutic strategies in low and high-risk MDS: what does the future have to offer? Blood Rev. 2021;45: 100689.","journal-title":"Blood Rev"},{"key":"570_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100649","volume":"41","author":"E Kaphan","year":"2020","unstructured":"Kaphan E, Laurin D, Lafeuillade B, Drillat P, Park S. Impact of transfusion on survival in patients with myelodysplastic syndromes: current knowledge, new insights and transfusion clinical practice. Blood Rev. 2020;41: 100649.","journal-title":"Blood Rev"},{"issue":"1","key":"570_CR192","first-page":"874","volume":"26","author":"Y Wang","year":"2021","unstructured":"Wang Y, Huang L, Hua Y, Liu H, Jiang H, Wang H, et\u00a0al. Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China. Hematology (Amsterdam, Netherlands). 2021;26(1):874\u201380.","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"6","key":"570_CR193","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1182\/blood-2014-03-563221","volume":"124","author":"N Shenoy","year":"2014","unstructured":"Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124(6):873\u201381.","journal-title":"Blood"},{"issue":"Suppl 1","key":"570_CR194","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S0268-960X(09)70006-2","volume":"23","author":"M Schmid","year":"2009","unstructured":"Schmid M. Iron chelation therapy in MDS: what have we learnt recently? Blood Rev. 2009;23(Suppl 1):S21\u20135.","journal-title":"Blood Rev"},{"issue":"1","key":"570_CR195","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.blre.2010.09.003","volume":"25","author":"HA Leitch","year":"2011","unstructured":"Leitch HA. Controversies surrounding iron chelation therapy for MDS. Blood Rev. 2011;25(1):17\u201331.","journal-title":"Blood Rev"},{"issue":"5","key":"570_CR196","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.blre.2018.03.002","volume":"32","author":"AM Zeidan","year":"2018","unstructured":"Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: that is the question! Blood Rev. 2018;32(5):368\u201377.","journal-title":"Blood Rev"},{"issue":"8","key":"570_CR197","doi-asserted-by":"publisher","first-page":"513","DOI":"10.7326\/M19-0916","volume":"172","author":"E Angelucci","year":"2020","unstructured":"Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, et\u00a0al. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial. Ann Intern Med. 2020;172(8):513\u201322.","journal-title":"Ann Intern Med"},{"issue":"1","key":"570_CR198","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bjh.14825","volume":"179","author":"HA Leitch","year":"2017","unstructured":"Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, et\u00a0al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179(1):83\u201397.","journal-title":"Br J Haematol"},{"issue":"8","key":"570_CR199","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(8):1307\u201325.","journal-title":"Am J Hematol"},{"issue":"3","key":"570_CR200","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3324\/haematol.2018.212332","volume":"105","author":"M Hoeks","year":"2020","unstructured":"Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, et\u00a0al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica. 2020;105(3):640\u201351.","journal-title":"Haematologica"},{"issue":"1","key":"570_CR201","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et\u00a0al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9\u201316.","journal-title":"Blood"},{"issue":"9","key":"570_CR202","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","volume":"35","author":"JA Kennedy","year":"2017","unstructured":"Kennedy JA, Ebert BL. Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol. 2017;35(9):968\u201374.","journal-title":"J Clin Oncol"},{"issue":"9","key":"570_CR203","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","volume":"97","author":"N Gattermann","year":"2012","unstructured":"Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et\u00a0al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematol the Hematol J. 2012;97(9):1364\u201371.","journal-title":"Haematol the Hematol J"},{"issue":"5","key":"570_CR204","first-page":"547","volume":"35","author":"X Chai","year":"2013","unstructured":"Chai X, Zhao M-F, Li D-G, Meng J-X, Lu W-Y, Mu J, et\u00a0al. Establishment of an mouse model of iron-overload and its impact on bone marrow hematopoiesis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013;35(5):547\u201352.","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"issue":"10","key":"570_CR205","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3324\/haematol.2018.193128","volume":"103","author":"X Jin","year":"2018","unstructured":"Jin X, He X, Cao X, Xu P, Xing Y, Sui S, et\u00a0al. Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice. Haematologica. 2018;103(10):1627\u201334.","journal-title":"Haematologica"},{"key":"570_CR206","doi-asserted-by":"publisher","first-page":"8855038","DOI":"10.1155\/2020\/8855038","volume":"2020","author":"L Huang","year":"2020","unstructured":"Huang L, Liu Z, Liu H, Ding K, Mi F, Xiang C, et\u00a0al. Iron overload impairs bone marrow mesenchymal stromal cells from higher-risk MDS patients by regulating the ROS-related Wnt\/\u03b2-Catenin pathway. Stem Cells Int. 2020;2020:8855038.","journal-title":"Stem Cells Int"},{"key":"570_CR207","doi-asserted-by":"publisher","first-page":"10181","DOI":"10.1038\/srep10181","volume":"5","author":"X Chai","year":"2015","unstructured":"Chai X, Li D, Cao X, Zhang Y, Mu J, Lu W, et\u00a0al. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem\/progenitor cells in mice. Sci Rep. 2015;5:10181.","journal-title":"Sci Rep"},{"issue":"6","key":"570_CR208","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.blre.2018.04.004","volume":"32","author":"A Isidori","year":"2018","unstructured":"Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, et\u00a0al. Iron toxicity - its effect on the bone marrow. Blood Rev. 2018;32(6):473\u20139.","journal-title":"Blood Rev"},{"key":"570_CR209","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.redox.2018.01.015","volume":"16","author":"C Heged\u0171s","year":"2018","unstructured":"Heged\u0171s C, Kov\u00e1cs K, Polg\u00e1r Z, Regdon Z, Szab\u00f3 \u00c9, Robaszkiewicz A, et\u00a0al. Redox control of cancer cell destruction. Redox Biol. 2018;16:59\u201374.","journal-title":"Redox Biol"},{"key":"570_CR210","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.mam.2018.02.003","volume":"63","author":"V Helfinger","year":"2018","unstructured":"Helfinger V, Schr\u00f6der K. Redox control in cancer development and progression. Mol Aspects Med. 2018;63:88\u201398.","journal-title":"Mol Aspects Med"},{"issue":"8","key":"570_CR211","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40265-016-0585-0","volume":"76","author":"LJ Scott","year":"2016","unstructured":"Scott LJ. Azacitidine: a review in myelodysplastic syndromes and acute myeloid leukaemia. Drugs. 2016;76(8):889\u2013900.","journal-title":"Drugs"},{"issue":"2","key":"570_CR212","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/leu.2013.265","volume":"28","author":"M Grovdal","year":"2014","unstructured":"Grovdal M, Karimi M, Tobiasson M, Reinius L, Jansson M, Ekwall K, et\u00a0al. Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation. Leukemia. 2014;28(2):411\u20133.","journal-title":"Leukemia"},{"issue":"12","key":"570_CR213","first-page":"1324","volume":"87","author":"G Leone","year":"2002","unstructured":"Leone G, Teofili L, Voso MT, Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87(12):1324\u201341.","journal-title":"Haematologica"},{"issue":"1","key":"570_CR214","first-page":"139","volume":"11","author":"P Montes","year":"2022","unstructured":"Montes P, Guerra-Librero A, Garc\u00eda P, Cornejo-Calvo ME, L\u00f3pez MDS, Haro TD, et\u00a0al. Effect of 5-Azacitidine treatment on redox status and inflammatory condition in MDS patients. Antioxidants (Basel, Switzerland). 2022;11(1):139.","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"570_CR215","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fphar.2018.01380","volume":"9","author":"S Klobuch","year":"2018","unstructured":"Klobuch S, Steinberg T, Bruni E, Mirbeth C, Heilmeier B, Ghibelli L, et\u00a0al. Biomodulatory treatment with Azacitidine, all-trans retinoic acid and pioglitazone induces differentiation of primary AML blasts into neutrophil like cells capable of ROS production and phagocytosis. Front Pharmacol. 2018;9:1380.","journal-title":"Front Pharmacol"},{"issue":"22","key":"570_CR216","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.12998\/wjcc.v8.i22.5657","volume":"8","author":"H Hasunuma","year":"2020","unstructured":"Hasunuma H, Shimizu N, Yokota H, Tatsuno I. Azacitidine decreases reactive oxygen species production in peripheral white blood cells: a case report. World J Clin Cases. 2020;8(22):5657\u201362.","journal-title":"World J Clin Cases"},{"issue":"12","key":"570_CR217","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ajh.26667","volume":"97","author":"NJ Short","year":"2022","unstructured":"Short NJ, Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions. Am J Hematol. 2022;97(12):1616\u201326.","journal-title":"Am J Hematol"},{"issue":"3","key":"570_CR218","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3892\/ijo.2012.1546","volume":"41","author":"DY Shin","year":"2012","unstructured":"Shin DY, Park Y-S, Yang K, Kim G-Y, Kim W-J, Han MH, et\u00a0al. Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation. Int J Oncol. 2012;41(3):910\u20138.","journal-title":"Int J Oncol"},{"key":"570_CR219","doi-asserted-by":"crossref","first-page":"8877460","DOI":"10.1155\/2021\/8877460","volume":"2021","author":"L Li","year":"2021","unstructured":"Li L, Liu W, Sun Q, Zhu H, Hong M, Qian S. Decitabine downregulates TIGAR to induce apoptosis and autophagy in myeloid leukemia cells. Oxid Med Cell Longev. 2021;2021:8877460.","journal-title":"Oxid Med Cell Longev"},{"key":"570_CR220","first-page":"2951519","volume":"2023","author":"F Du","year":"2023","unstructured":"Du F, Jin T, Wang L. Mechanism of action of Decitabine in the treatment of acute myeloid leukemia by regulating LINC00599. Anal Cell Pathol (Amst). 2023;2023:2951519.","journal-title":"Anal Cell Pathol (Amst)"},{"issue":"5","key":"570_CR221","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1158\/1078-0432.CCR-13-1453","volume":"20","author":"TE Fandy","year":"2014","unstructured":"Fandy TE, Jiemjit A, Thakar M, Rhoden P, Suarez L, Gore SD. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin Cancer Res. 2014;20(5):1249\u201358.","journal-title":"Clin Cancer Res"},{"key":"570_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172676","volume":"863","author":"L Wang","year":"2019","unstructured":"Wang L, Guo X, Guo X, Zhang X, Ren J. Decitabine promotes apoptosis in mesenchymal stromal cells isolated from patients with myelodysplastic syndromes by inducing reactive oxygen species generation. Eur J Pharmacol. 2019;863: 172676.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"570_CR223","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41375-018-0139-4","volume":"32","author":"S Kayser","year":"2018","unstructured":"Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia. 2018;32(6):1277\u201394.","journal-title":"Leukemia"},{"key":"570_CR224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-018-0797-0","volume":"37","author":"R Prieto-Bermejo","year":"2018","unstructured":"Prieto-Bermejo R, Romo-Gonzalez M, Perez-Fernandez A, Ijurko C, Hernandez-Hernandez A. Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side. J Exp Clin Cancer Res. 2018;37:1\u201318.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"570_CR225","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-020-00242-z","volume":"8","author":"NM Kaweme","year":"2020","unstructured":"Kaweme NM, Zhou S, Changwe GJ, Zhou F. The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications. Biomark Res. 2020;8(1):1\u201312.","journal-title":"Biomark Res"},{"issue":"3","key":"570_CR226","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.leukres.2007.06.006","volume":"32","author":"J Wang","year":"2008","unstructured":"Wang J, Li L, Cang H, Shi G, Yi J. NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res. 2008;32(3):429\u201336.","journal-title":"Leuk Res"},{"issue":"7","key":"570_CR227","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1136\/jim-2018-000953","volume":"67","author":"L Huang","year":"2019","unstructured":"Huang L, Liu Z, Jiang H, Li L, Fu R. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis. J Investig Med. 2019;67(7):1067\u201375.","journal-title":"J Investig Med"},{"issue":"4","key":"570_CR228","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41416-022-02074-0","volume":"128","author":"L Wang","year":"2023","unstructured":"Wang L, Zhang Q, Ye L, Ye X, Yang W, Zhang H, et\u00a0al. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RAR\u03b1-Nrf2 complex. Br J Cancer. 2023;128(4):691\u2013701.","journal-title":"Br J Cancer"},{"key":"570_CR229","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2017.04.005","volume":"47","author":"MDPS Idelchik","year":"2017","unstructured":"Idelchik MDPS, Begley U, Begley TJ, Melendez JA. Mitochondrial ROS control of cancer. Semin Cancer Biol. 2017;47:57\u201366.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"570_CR230","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931\u201347.","journal-title":"Nat Rev Drug Discov"},{"key":"570_CR231","doi-asserted-by":"publisher","first-page":"6917206","DOI":"10.1155\/2018\/6917206","volume":"2018","author":"J Luo","year":"2018","unstructured":"Luo J, Xiang Y, Xu X, Fang D, Li D, Ni F, et\u00a0al. High glucose-induced ROS production stimulates proliferation of pancreatic cancer via inactivating the JNK pathway. Oxid Med Cell Longev. 2018;2018:6917206.","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"570_CR232","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jsps.2017.12.013","volume":"26","author":"K Singh","year":"2018","unstructured":"Singh K, Bhori M, Kasu YA, Bhat G, Marar T. Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity\u2014exploring the armoury of obscurity. Saudi Pharm J. 2018;26(2):177\u201390.","journal-title":"Saudi Pharm J"},{"issue":"6","key":"570_CR233","first-page":"1128","volume":"11","author":"M Luo","year":"2022","unstructured":"Luo M, Zhou L, Huang Z, Li B, Nice EC, Xu J, et\u00a0al. Antioxidant therapy in cancer: rationale and progress. Antioxidants (Basel, Switzerland). 2022;11(6):1128.","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"4","key":"570_CR234","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.drudis.2018.01.021","volume":"23","author":"RK Khurana","year":"2018","unstructured":"Khurana RK, Jain A, Jain A, Sharma T, Singh B, Kesharwani P. Administration of antioxidants in cancer: debate of the decade. Drug Discov Today. 2018;23(4):763\u201370.","journal-title":"Drug Discov Today"},{"key":"570_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101864","volume":"42","author":"MS Petronek","year":"2021","unstructured":"Petronek MS, Stolwijk JM, Murray SD, Steinbach EJ, Zakharia Y, Buettner GR, et\u00a0al. Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy. Redox Biol. 2021;42: 101864.","journal-title":"Redox Biol"},{"issue":"10","key":"570_CR236","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","volume":"133","author":"U Platzbecker","year":"2019","unstructured":"Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096\u2013107.","journal-title":"Blood"},{"issue":"4","key":"570_CR237","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.freeradbiomed.2012.06.006","volume":"53","author":"S Kikuchi","year":"2012","unstructured":"Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, et\u00a0al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radical Biol Med. 2012;53(4):643\u20138.","journal-title":"Free Radical Biol Med"},{"issue":"17","key":"570_CR238","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","volume":"30","author":"AF List","year":"2012","unstructured":"List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et\u00a0al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30(17):2134\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"570_CR239","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjh.16013","volume":"187","author":"T Jim\u00e9nez-Solas","year":"2019","unstructured":"Jim\u00e9nez-Solas T, L\u00f3pez-Cadenas F, Aires-Mej\u00eda I, Caballero-Berrocal JC, Ortega R, Redondo AM, et\u00a0al. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity. Br J Haematol. 2019;187(1):93\u2013104.","journal-title":"Br J Haematol"},{"key":"570_CR240","doi-asserted-by":"publisher","first-page":"1295984","DOI":"10.1155\/2020\/1295984","volume":"2020","author":"D Zhang","year":"2020","unstructured":"Zhang D, Luo Z, Jin Y, Chen Y, Yang T, Yang Q, et\u00a0al. Azelaic acid exerts antileukemia effects against acute myeloid leukemia by regulating the Prdxs\/ROS signaling pathway. Oxid Med Cell Longev. 2020;2020:1295984.","journal-title":"Oxid Med Cell Longev"},{"key":"570_CR241","doi-asserted-by":"publisher","first-page":"930205","DOI":"10.3389\/fcell.2022.930205","volume":"10","author":"S Travaglini","year":"2022","unstructured":"Travaglini S, Gurnari C, Antonelli S, Silvestrini G, Noguera NI, Ottone T, et\u00a0al. The anti-leukemia effect of ascorbic acid: from the pro-oxidant potential to the epigenetic role in acute myeloid leukemia. Front Cell Dev Biol. 2022;10:930205.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"570_CR242","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.3390\/nu11112808","volume":"11","author":"P Ghanem","year":"2019","unstructured":"Ghanem P, Zouein A, Mohamad M, Hodroj MH, Haykal T, Abou Najem S, et\u00a0al. The Vitamin E derivative gamma tocotrienol promotes anti-tumor effects in acute myeloid leukemia cell lines. Nutrients. 2019;11(11):2808.","journal-title":"Nutrients"},{"issue":"9","key":"570_CR243","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3390\/nu12092629","volume":"12","author":"MH Hodroj","year":"2020","unstructured":"Hodroj MH, Al Bast NAH, Taleb RI, Borjac J, Rizk S. Nettle tea inhibits growth of acute myeloid leukemia cells in vitro by promoting apoptosis. Nutrients. 2020;12(9):2629.","journal-title":"Nutrients"},{"issue":"1","key":"570_CR244","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13046-018-0948-3","volume":"37","author":"Y Jin","year":"2018","unstructured":"Jin Y, Yang Q, Liang L, Ding L, Liang Y, Zhang D, et\u00a0al. Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs\/ROS\/Trx1 signalling pathway. J Exp Clin Cancer Res CR. 2018;37(1):277.","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"9","key":"570_CR245","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.leukres.2009.03.027","volume":"33","author":"J Schanz","year":"2009","unstructured":"Schanz J, Jung H, Woermann B, Gassmann W, Petersen T, Hinke A, et\u00a0al. Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes. Leuk Res. 2009;33(9):1183\u20138.","journal-title":"Leuk Res"},{"issue":"3","key":"570_CR246","first-page":"117","volume":"22","author":"M \u00c7etiner","year":"2005","unstructured":"\u00c7etiner M, F\u0131ratl\u0131 Tu\u011flular T, \u00d6zen Al Ahdab Y, Al Ahdab H, K\u00f6se M, Noyan F, et\u00a0al. Amifostine treatment in patients with myelodysplastic syndrome. Turk J Haematol. 2005;22(3):117\u201323.","journal-title":"Turk J Haematol"},{"key":"570_CR247","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2017.12.009","volume":"66","author":"H Zhao","year":"2018","unstructured":"Zhao H, Zhu H, Huang J, Zhu Y, Hong M, Zhu H, et\u00a0al. The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk Res. 2018;66:1\u20137.","journal-title":"Leuk Res"},{"issue":"10","key":"570_CR248","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3109\/07357907.2011.626479","volume":"29","author":"A Nakayama","year":"2011","unstructured":"Nakayama A, Alladin KP, Igbokwe O, White JD. Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy. Cancer Invest. 2011;29(10):655\u201367.","journal-title":"Cancer Invest"},{"issue":"20","key":"570_CR249","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1074\/jbc.M110.103713","volume":"285","author":"F-L Zhou","year":"2010","unstructured":"Zhou F-L, Zhang W-G, Wei Y-C, Meng S, Bai G-G, Wang B-Y, et\u00a0al. Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem. 2010;285(20):15010\u20135.","journal-title":"J Biol Chem"},{"issue":"9","key":"570_CR250","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/leu.2017.192","volume":"31","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, et\u00a0al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017;31(9):1944\u201350.","journal-title":"Leukemia"},{"issue":"6","key":"570_CR251","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/leu.2013.16","volume":"27","author":"C Kelaidi","year":"2013","unstructured":"Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, et\u00a0al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 2013;27(6):1283\u201390.","journal-title":"Leukemia"},{"issue":"8","key":"570_CR252","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2011.194","volume":"305","author":"MJ Olnes","year":"2011","unstructured":"Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syndromes. JAMA. 2011;305(8):814\u20139.","journal-title":"JAMA"},{"issue":"4","key":"570_CR253","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.seminhematol.2012.07.004","volume":"49","author":"AR Parikh","year":"2012","unstructured":"Parikh AR, Olnes MJ, Barrett AJ. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. Semin Hematol. 2012;49(4):304\u201311.","journal-title":"Semin Hematol"},{"issue":"35","key":"570_CR254","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1200\/JCO.2010.29.7010","volume":"28","author":"EM Sloand","year":"2010","unstructured":"Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K, et\u00a0al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010;28(35):5166\u201373.","journal-title":"J Clin Oncol"},{"issue":"8","key":"570_CR255","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/s41375-023-01949-2","volume":"37","author":"M Schneider","year":"2023","unstructured":"Schneider M, Rolfs C, Trumpp M, Winter S, Fischer L, Richter M, et\u00a0al. Activation of distinct inflammatory pathways in subgroups of LR-MDS. Leukemia. 2023;37(8):1709\u201318.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"570_CR256","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2022-167703","volume":"140","author":"G Garcia-Manero","year":"2022","unstructured":"Garcia-Manero G, Adema V, Urrutia S, Ma F, Yang H, Ganan-Gomez I, et\u00a0al. Clinical and biological effects of Canakinumab in lower-risk myelodysplastic syndromes (MDS): results from a phase 2 clinical trial. Blood. 2022;140(Supplement 1):2078\u201380.","journal-title":"Blood"},{"issue":"Supplement 1","key":"570_CR257","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2023-185259","volume":"142","author":"JJ Rodriguez Sevilla","year":"2023","unstructured":"Rodriguez Sevilla JJ, Adema V, Chien KS, Ganan-Gomez I, Montalban-Bravo G, Urrutia S, et\u00a0al. A phase 2 study of Canakinumab in patients with lower-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood. 2023;142(Supplement 1):1866.","journal-title":"Blood"},{"issue":"3","key":"570_CR258","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.8","volume":"4","author":"M Tobiasson","year":"2014","unstructured":"Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, et\u00a0al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: results from the nordic NMDSG08A phase II trial. Blood Cancer J. 2014;4(3): e189.","journal-title":"Blood Cancer J"},{"issue":"4","key":"570_CR259","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/leu.2015.265","volume":"30","author":"G Garcia-Manero","year":"2016","unstructured":"Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, et\u00a0al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016;30(4):889\u201396.","journal-title":"Leukemia"},{"issue":"13","key":"570_CR260","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1200\/JCO.20.02619","volume":"39","author":"G Garcia-Manero","year":"2021","unstructured":"Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, et\u00a0al. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2021;39(13):1426\u201336.","journal-title":"J Clin Oncol"},{"issue":"25","key":"570_CR261","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","volume":"34","author":"V Santini","year":"2016","unstructured":"Santini V, Almeida A, Giagounidis A, Gr\u00f6pper S, Jonasova A, Vey N, et\u00a0al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34(25):2988\u201396.","journal-title":"J Clin Oncol"},{"issue":"4","key":"570_CR262","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/leu.2015.296","volume":"30","author":"A Toma","year":"2016","unstructured":"Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, et\u00a0al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016;30(4):897\u2013905.","journal-title":"Leukemia"},{"issue":"12","key":"570_CR263","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/leu.2016.228","volume":"30","author":"E Negoro","year":"2016","unstructured":"Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, et\u00a0al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 2016;30(12):2405\u20139.","journal-title":"Leukemia"},{"issue":"15","key":"570_CR264","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","volume":"29","author":"M J\u00e4dersten","year":"2011","unstructured":"J\u00e4dersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, G\u00f6hring G, et\u00a0al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"570_CR265","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et\u00a0al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140\u201351.","journal-title":"N Engl J Med"},{"issue":"5","key":"570_CR266","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41375-019-0420-1","volume":"33","author":"A Bataller","year":"2019","unstructured":"Bataller A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G. The role of TGF\u03b2 in hematopoiesis and myeloid disorders. Leukemia. 2019;33(5):1076\u201389.","journal-title":"Leukemia"},{"issue":"10399","key":"570_CR267","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","volume":"402","author":"U Platzbecker","year":"2023","unstructured":"Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, et\u00a0al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2023;402(10399):373\u201385.","journal-title":"Lancet (London, England)"},{"issue":"3","key":"570_CR268","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","volume":"4","author":"EN Oliva","year":"2017","unstructured":"Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, et\u00a0al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4(3):e127\u201336.","journal-title":"Lancet Haematol"},{"issue":"1","key":"570_CR269","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/JCO.20.01895","volume":"39","author":"DP Steensma","year":"2021","unstructured":"Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, et\u00a0al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021;39(1):48\u201356.","journal-title":"J Clin Oncol"},{"issue":"10423","key":"570_CR270","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","volume":"403","author":"U Platzbecker","year":"2024","unstructured":"Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, et\u00a0al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2024;403(10423):249\u201360.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"570_CR271","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ajh.26763","volume":"98","author":"P Vittayawacharin","year":"2023","unstructured":"Vittayawacharin P, Kongtim P, Ciurea SO. Allogeneic stem cell transplantation for patients with myelodysplastic syndromes. Am J Hematol. 2023;98(2):322\u201337.","journal-title":"Am J Hematol"},{"issue":"13","key":"570_CR272","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T de Witte","year":"2017","unstructured":"de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et\u00a0al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753\u201362.","journal-title":"Blood"},{"issue":"15","key":"570_CR273","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M L\u00fcbbert","year":"2011","unstructured":"L\u00fcbbert M, Suciu S, Baila L, R\u00fcter BH, Platzbecker U, Giagounidis A, et\u00a0al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987\u201396.","journal-title":"J Clin Oncol"},{"issue":"1","key":"570_CR274","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O\u2019Brien S, Cortes J, et\u00a0al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52\u20137.","journal-title":"Blood"},{"issue":"23","key":"570_CR275","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","volume":"27","author":"DP Steensma","year":"2009","unstructured":"Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, et\u00a0al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009;27(23):3842\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"570_CR276","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, et\u00a0al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024;11(1):e15\u201326.","journal-title":"Lancet Haematol"},{"issue":"3","key":"570_CR277","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et\u00a0al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332.","journal-title":"Lancet Oncol"},{"issue":"12","key":"570_CR278","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, et\u00a0al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668\u201379.","journal-title":"Lancet Oncol"},{"key":"570_CR279","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.redox.2016.12.035","volume":"11","author":"H Sies","year":"2017","unstructured":"Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: oxidative eustress. Redox Biol. 2017;11:613\u20139.","journal-title":"Redox Biol"},{"issue":"26","key":"570_CR280","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1182\/blood-2009-07-234062","volume":"114","author":"V Pullarkat","year":"2009","unstructured":"Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood. 2009;114(26):5251\u20135.","journal-title":"Blood"},{"issue":"21","key":"570_CR281","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood.V116.21.122.122","volume":"116","author":"LSA Chan","year":"2010","unstructured":"Chan LSA, Gu LC, Rauh MJ, Wells RA. Iron overload accelerates development of leukaemia: evidence from a mouse model. Blood. 2010;116(21):122.","journal-title":"Blood"},{"issue":"3","key":"570_CR282","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1189\/jlb.0113006","volume":"94","author":"F Zhou","year":"2013","unstructured":"Zhou F, Shen Q, Claret FX. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. J Leukoc Biol. 2013;94(3):423\u20139.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"570_CR283","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.leukres.2013.07.008","volume":"38","author":"YJ Chung","year":"2014","unstructured":"Chung YJ, Robert C, Gough SM, Rassool FV, Aplan PD. Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome. Leukemia Res. 2014;38(1):95\u2013102.","journal-title":"Leukemia Res"},{"issue":"5","key":"570_CR284","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41419-018-0552-7","volume":"9","author":"Q Zheng","year":"2018","unstructured":"Zheng Q, Zhao Y, Guo J, Zhao S, Fei C, Xiao C, et\u00a0al. Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK\/MFF\/Drp1 pathway. Cell Death Dis. 2018;9(5):515.","journal-title":"Cell Death Dis"},{"issue":"3","key":"570_CR285","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/cells8030226","volume":"8","author":"H Tanaka","year":"2019","unstructured":"Tanaka H, Espinoza JL, Fujiwara R, Rai S, Morita Y, Ashida T, et\u00a0al. Excessive reactive iron impairs hematopoiesis by affecting both immature hematopoietic cells and stromal cells. Cells. 2019;8(3):226.","journal-title":"Cells"},{"key":"570_CR286","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3389\/fphar.2020.00399","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, He M, Zhang W, Yang M, Ding Y, Xu S, et\u00a0al. Antioxidant small molecule compound chrysin promotes the self-renewal of hematopoietic stem cells. Front Pharmacol. 2020;11:399.","journal-title":"Front Pharmacol"},{"issue":"6","key":"570_CR287","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/JLB.1A0520-179R","volume":"108","author":"Y Dong","year":"2020","unstructured":"Dong Y, Bai J, Zhang Y, Zhou Y, Pan X, Li X, et\u00a0al. Alpha lipoic acid promotes development of hematopoietic progenitors derived from human embryonic stem cells by antagonizing ROS signals. J Leukoc Biol. 2020;108(6):1711\u201325.","journal-title":"J Leukoc Biol"},{"issue":"8","key":"570_CR288","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3324\/haematol.2019.226936","volume":"105","author":"E Henry","year":"2020","unstructured":"Henry E, Souissi-Sahraoui I, Deynoux M, Lef\u00e8vre A, Barroca V, Campalans A, et\u00a0al. Human hematopoietic stem\/progenitor cells display reactive oxygen species-dependent long-term hematopoietic defects after exposure to low doses of ionizing radiations. Haematologica. 2020;105(8):2044\u201355.","journal-title":"Haematologica"},{"issue":"1","key":"570_CR289","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/stmcls\/sxac072","volume":"41","author":"K Harada","year":"2023","unstructured":"Harada K, Yahata T, Onizuka M, Ishii T, Aziz Ibrahim A, Kikkawa E, et\u00a0al. Mitochondrial electron transport chain complex II dysfunction causes premature aging of hematopoietic stem cells. Stem Cells. 2023;41(1):39\u201349.","journal-title":"Stem Cells"},{"issue":"5","key":"570_CR290","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.3892\/mmr.2016.5779","volume":"14","author":"H-Y Hua","year":"2016","unstructured":"Hua H-Y, Gao H-Q, Sun A-N, Cen J-N, Wu L-L. Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM-1 human myelodysplastic syndrome cell line. Mol Med Rep. 2016;14(5):4180\u20136.","journal-title":"Mol Med Rep"},{"issue":"1","key":"570_CR291","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/hematolrep15010010","volume":"15","author":"X Hu","year":"2023","unstructured":"Hu X, Li L, Nkwocha J, Sharma K, Zhou L, Grant S. Synergistic interactions between the hypomethylating agent thio-deoxycytidine and venetoclax in myelodysplastic syndrome cells. Hematol Rep. 2023;15(1):91\u2013100.","journal-title":"Hematol Rep"},{"issue":"44","key":"570_CR292","doi-asserted-by":"publisher","first-page":"77436","DOI":"10.18632\/oncotarget.20497","volume":"8","author":"KZ Oben","year":"2017","unstructured":"Oben KZ, Alhakeem SS, McKenna MK, Brandon JA, Mani R, Noothi SK, et\u00a0al. Oxidative stress-induced JNK\/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A. Oncotarget. 2017;8(44):77436\u201352.","journal-title":"Oncotarget"},{"issue":"2","key":"570_CR293","first-page":"1106","volume":"42","author":"W Dong","year":"2018","unstructured":"Dong W, Lin Y, Cao Y, Liu Y, Xie X, Gu W. Luteolin induces myelodysplastic syndrome-derived cell apoptosis via the p53-dependent mitochondrial signaling pathway mediated by reactive oxygen species. Int J Mol Med. 2018;42(2):1106\u201315.","journal-title":"Int J Mol Med"},{"issue":"6","key":"570_CR294","first-page":"1851","volume":"29","author":"H-Y Niu","year":"2021","unstructured":"Niu H-Y, Shao Z-H, Wang H-Q. Inhibitory effect of ascorbic acid on myelodysplastic syndrome cells and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(6):1851\u20137.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"5","key":"570_CR295","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.3892\/mmr.2015.4252","volume":"12","author":"C Wei","year":"2015","unstructured":"Wei C, Xiao Q, Kuang X, Zhang T, Yang Z, Wang L. Fucoidan inhibits proliferation of the SKM-1 acute myeloid leukaemia cell line via the activation of apoptotic pathways and production of reactive oxygen species. Mol Med Rep. 2015;12(5):6649\u201355.","journal-title":"Mol Med Rep"}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-024-00570-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-024-00570-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-024-00570-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T06:33:40Z","timestamp":1731738820000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmbl.biomedcentral.com\/articles\/10.1186\/s11658-024-00570-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,14]]},"references-count":295,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1186\/s11658-024-00570-0","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,14]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}